Sellas Life Sciences is trading 11.68% down at $9.57 following its July 27 earnings update and a significant legal setback involving a lost binding arbitration case against 3D Medicines.
- The company reported $138.3 million in cash, but investor sentiment is being driven primarily by the unfavorable arbitration ruling and resulting legal headlines.
- The selloff appears company-specific as the broader biotech sector is currently firmer; the stock is continuing to reprice after falling 4.28% in the prior session.
- Markets are reacting to the combined impact of the financial results and the legal developments as they assess the company's forward outlook.